Loratadine-loaded Niosomal Transdermal Patch for Treating Allergic Issues: A Design Expert’s Associated Fabrication and Evaluation
Introduction: Loratadine (LRD) is a second-generation H1 histamine
antagonist and is helpful in the treatment of allergies.
Methods: The Box Behnken design (BBD) was used in this study to
create nine LRD niosomes, which were then cast in solvent and put on
transdermal patches. The niosomes’ dimensions, shape, zeta potential,
and degree of entrapment efficiency were then assessed. On the LRD
entrapment, the niosomes’ cholesterol, Span-40, Span-60, and Span-80
concentrations were measured. The patch system was filled with the
optimised niosomal formulations. Then, each patch was described using its
physicochemical properties and results from in vitro permeation studies.
Results: Patches containing niosomal vesicles, in contrast to control
patches, demonstrated improved drug release. It was shown that
niosomal patches exhibited greater penetration than control patches.
Niosomes’ surfactant serves as a permeation enhancer and enhances
LRD permeation from niosomes.
Conclusion: The study concluded that the niosome-based transdermal
patches might effectively distribute LRD medications trans-dermally
while minimising GIT adverse effects.
How to cite this article:
Sailaja C, Bhupalam PK. Loratadine-loaded
Niosomal Transdermal Patch for Treating Allergic
Issues: A Design Expert’s Associated Fabrication
and Evaluation. Chettinad Health City Med J.
Shravani Y, Ahad HA, Haranath C, Poojitha BG, Rahamathulla S, Rupasree A. Past decade work done on cubosomes and its factorial design: a fast track information for researchers. Int J Life Sci Pharma Res. 2021;11(1):124-35. [Google Scholar]
Bandagisa F, Ahad HA, Charan DS, Vidya JS, Chandana RU, Nandini RP. Fabrication and evaluation of cefpodoxime proxetil niosomes. Asian J Pharm Technol. 2022;12(2):109-12. [Google Scholar]
Amado JR, Prada AL, Duarte JL, Keita H, da Silva HR, Ferreira AM, Sosa EH, Carvalho JC. Development, stability and in vitro delivery profile of new loratadine loaded nanoparticles. Saudi Pharm J. 2017;25(8):1158-68. [PubMed] [Google Scholar]